Heart disease is the leading cause of death in the U.S., killing one person nearly every minute. Coronary heart disease--a group of disorders that result in a reduction in blood flow through the heart--affects more than 15.8 million people in the country, while heart failure has become the main reason that more than 5 million people endure 12 million to 15 million medical visits and 6.5 million to 7.0 million days spent in the hospital each year.
Current and emerging products enabling CABG and PCI myocardial revascularization procedures include automated anastomosis/anastomosis-assist devices, drug-eluting coronary stent systems, and drug-eluting PTCA balloon systems. Sales of these products--along with transmyocardial revascularization systems and anti-atherosclerosis biotherapy products for myocardial revascularization, as well as cell-based and device-based products for myocardial repair/regeneration--are projected to reach an estimated $4,126.5 million in the U.S. in the year 2011.
This dynamic, new report from Medtech Insight includes analyses of products, current and emerging markets, competitors, and opportunities in the fields of myocardial revascularization and repair/regeneration.
Covered topics in this report include anti-atherosclerosis biotherapy products; automated anastomosis/anastomosis-assist procedures and devices; bioabsorbable and biological material-carrying stent systems; cardiac structural support and modification technologies; cardiovascular phototherapy; cell-based and gene-based myocardial tissue repair/regeneration technologies; conventional, less-invasive, and transcatheter coronary artery bypass graft surgery; direct cardiac compression devices; drug-eluting coronary stent systems; drug-eluting PTCA balloon systems; endothelial progenitor cell capture antibody and antisense technologies; heart disease statistics; surgical ventricular restoration devices; therapeutic angiogenesis; and transmyocardial revascularization systems.
TABLE OF CONTENTS:
i. Current and Emerging Markets for Selected Myocardial Revascularization Technologies and Products
a. Facilitated Anastomosis Devices
b. Drug-Eluting Balloon Angioplasty Systems
c. Drug-Eluting Stent Systems
d. Transmyocardial Revascularization Systems
e. Atherosclerosis Management Biotherapy Products
ii. Current and Emerging Markets for Selected Myocardial Repair/Regeneration Technologies and Products
a. Cell-Based Therapies for Myocardial Tissue Repair/Regeneration
b. Gene-Based Therapies for Myocardial Tissue Repair/Regeneration
c. Cardiac Structural Support/Modification Products
iii. Combined Market for Selected Current and Emerging Myocardial Revascularization, Repair, and Regeneration Technologies and Products
Exhibit ES-1: Current and Emerging Myocardial Revascularization Products, Combined Market Forecast, 2007-2011
Exhibit ES-2: Facilitated Anastomosis Devices Used in Coronary Artery Bypass Graft Surgery, Market Forecast, 2007-2011
Exhibit ES-3: Drug-Eluting Balloon Angioplasty Systems for Treatment of In-Stent Restenosis, Market Forecast, 2007-2011
Exhibit ES-4: Coronary Stent Systems, Market Forecast, 2007-2011
Exhibit ES-5: Transmyocardial Revascularization Products, Market Forecast, 2007-2011
Exhibit ES-6: Atherosclerosis Management Biotherapy Products, Market Forecast, 2007-2011
Exhibit ES-7: Current and Emerging Myocardial Repair/Regeneration Products, Combined Market Forecast, 2007-2011
Exhibit ES-8: Cell-Based Myocardial Tissue Repair/Regeneration Products, Market Forecast, 2007-2011
Exhibit ES-9: 2008, Selected Gene-Based Myocardial Tissue Repair/Regeneration Approaches under Investigation
Exhibit ES-10: Cardiac Support/Modification Devices, Market Forecast, 2007-2011
Exhibit ES-11: Current and Emerging Myocardial Revascularization, Repair, and Regeneration Products, Combined Market Forecast, 2007-2011
1. HEART DISEASE/DISORDER OVERVIEW
1.1 Heart Anatomy and Physiology
1.1.1 The Cardiac Conduction System
1.1.2 The Heart Valves
1.2 Selected Heart Diseases/Disorders
1.2.1 Coronary Heart Disease
18.104.22.168 Angina Pectoris
22.214.171.124 Myocardial Infarction
126.96.36.199 Systolic and Diastolic Pressures
1.2.3 Cardiac Dysrhythmia
188.8.131.52 Sick Sinus Syndrome
184.108.40.206 Heart Block
220.127.116.11 Atrial Fibrillation
18.104.22.168 Ventricular Fibrillation
22.214.171.124 Dilated Cardiomyopathy
126.96.36.199 Hypertrophic Cardiomyopathy
188.8.131.52 Restrictive Cardiomyopathy
1.2.5 Heart Valve Disorders
184.108.40.206 Valvular Stenosis
220.127.116.11 Valvular Regurgitation
18.104.22.168 Valve Prolapse
1.2.6 Heart Failure
22.214.171.124 Disease Development
126.96.36.199 Ejection Fraction Reduction
188.8.131.52 Classification/Staging Systems
Exhibit 1-1: Cross-Section Diagram of the Heart
Exhibit 1-2: Cross-Section Diagram of the Heart Valves
Exhibit 1-3: Statistics for Selected Heart Disease Risk Factors
Exhibit 1-4: Standard Angina Pectoris Classification
Exhibit 1-5: Angina Pectoris, Selected Statistics
Exhibit 1-6: Myocardial Infarction, Selected Statistics
Exhibit 1-7: 2007, Percentage of Adults Who Have Been Told They Have High Blood Pressure, by State
Exhibit 1-8: Hypertension, Selected Statistics
Exhibit 1-9: Cardiac Dysrhythmia, Selected Statistics
Exhibit 1-10: Cardiomyopathy, Selected Statistics
Exhibit 1-11: Heart Valve Disorders, Selected Statistics
Exhibit 1-12: Summary, New York Heart Association Heart Failure Classification System
Exhibit 1-13: Summary, American College of Cardiology/American Heart Association Heart Failure Staging System
Exhibit 1-14: Heart Failure, Selected Statistics
2. CURRENT AND EMERGING MYOCARDIAL REVASCULARIZATION TECHNOLOGIES
2.1 Myocardial Revascularization Technologies
2.1.1 Coronary Artery Bypass Graft Surgery
184.108.40.206 Conventional Coronary Artery Bypass Graft Surgery
220.127.116.11 Less Invasive Coronary Artery Bypass Graft Surgery
18.104.22.168.1 Minimally Invasive Direct Coronary Artery Bypass
22.214.171.124.2 Off-Pump Coronary Artery Bypass
126.96.36.199.3 Port Access Coronary Artery Bypass
188.8.131.52.4 Hybrid Coronary Artery Bypass
184.108.40.206.5 Robotic-Assisted Coronary Artery Bypass
220.127.116.11 Transcatheter Coronary Artery Bypass Techniques
18.104.22.168.1 Ventriculo-Coronary Artery Bypass
22.214.171.124.2 In Situ Coronary Artery Bypass
126.96.36.199 Caseload Volumes Forecast
2.1.2 Facilitated Anastomosis
188.8.131.52 Benefits Compared to Conventional Suturing
184.108.40.206 Procedure Volumes Forecast
2.1.3 Percutaneous Transluminal Coronary Angioplasty
220.127.116.11 Caseload Volumes Forecast
2.1.4 Drug-Eluting Balloon Angioplasty
18.104.22.168 Clinical Experience with Drug-Eluting Balloons
22.214.171.124.1 Studies Involving the Paccocath Drug-Eluting Balloon
126.96.36.199.2 Studies Involving the SeQuent Please Drug-Eluting Balloon
188.8.131.52 Regulatory Outlook for Drug-Eluting Balloons
184.108.40.206 Caseload Volumes Forecast
2.1.5 Coronary Stenting
220.127.116.11 Stenting with Bare-Metal and Drug-Eluting Devices
18.104.22.168.1 Stent Materials
22.214.171.124.1.1 Stainless Steel
126.96.36.199.1.4 Cobalt-Chromium Alloys
188.8.131.52.2 Stent Coatings/Surfaces and Anti-Restenosis Agents
184.108.40.206.2.6 Biolimus A9
220.127.116.11 Stenting with Bioabsorbable Devices
18.104.22.168.1 The Igaki-Tamai Bioabsorbable Stent
22.214.171.124.2 The Absorbable Metal Stent
126.96.36.199.3 The REVA Bioabsorbable Stent
188.8.131.52.4 The Bioabsorbable Everolimus-Eluting Stent
184.108.40.206.5 Regulatory Outlook
220.127.116.11 Stenting with Biological Material-Carrying Devices
18.104.22.168.1 Endothelial Progenitor Cell Capture Antibodies
22.214.171.124.2 Antisense Agents
126.96.36.199 Stent Delivery
188.8.131.52 Stent Deployment
184.108.40.206.1 Patients with Small Vessel Disease
220.127.116.11.2 Patients with Left Main Disease
18.104.22.168.1 Repeat Revascularization
22.214.171.124.2 Stent Thrombosis
126.96.36.199.3 Diabetes and Stenting
188.8.131.52.4 Stent-Associated ST-Segment Elevation Myocardial Infarction
184.108.40.206.5 Long Lesion Length and Restenosis
220.127.116.11 Caseload Volumes Forecast
2.1.6 Cardiovascular Phototherapy
2.1.7 Therapeutic Angiogenesis
18.104.22.168 Growth Factor-Based Therapy
22.214.171.124 Stem Cell-/Progenitor-Cell Based Therapy
2.1.8 Transmyocardial Revascularization
126.96.36.199 Laser-Based Transmyocardial Revascularization
188.8.131.52 Procedure Volumes Forecast
2.2 Atherosclerosis Management Biotherapies
2.2.1 Pharmacological Approaches to Atherosclerosis Management
2.2.2 Caseload Volumes Forecast
Exhibit 2-1: Advantages and Disadvantages of Conventional and Selected Minimally Invasive Coronary Artery Bypass Techniques
Exhibit 2-2: Advantages and Disadvantages of Selected Transcatheter Coronary Artery Bypass Techniques
Exhibit 2-3: Coronary Artery Bypass Graft Surgery, Caseload Volumes Forecast, 2007-2011
Exhibit 2-4: Facilitated Anastomosis Performed in Conjunction with Coronary Artery Bypass Graft Surgery, Procedure Volumes Forecast, 2007-2011
Exhibit 2-5: Percutaneous Transluminal Coronary Angioplasty, Caseload Volumes Forecast, 2007-2011
Exhibit 2-6: Pooled 24-Month Follow-Up Data for PACCOCATH-ISR I/II Trials
Exhibit 2-7: Six-Month Follow-Up Data for PEPCAD I-SVD Trial
Exhibit 2-8: Six-Month Follow-Up Data for PEPCAD II-ISR Trial
Exhibit 2-9: Drug-Eluting Balloon Angioplasty for In-Stent Restenosis, Caseload Volumes Forecast, 2007-2011
Exhibit 2-10: 2008, Selected Anti-Restenosis Agents
Exhibit 2-11: 2008, Selected Data from the PROGRESS-AMS and ABSORB Clinical Trials
Exhibit 2-12: Coronary Stenting, Caseload Volumes Forecast, 2007-2011
Exhibit 2-13: Growth Factor- and Stem Cell-Based Therapeutic Angiogenesis
Exhibit 2-14: Transmyocardial Revascularization, Procedure Volumes Forecast, 2007-2011
Exhibit 2-15: Atherosclerosis Management Biotherapies, Caseload Volumes Forecast, 2007-2011
3. CURRENT AND EMERGING MYOCARDIAL REPAIR/REGENERATION TECHNOLOGIES
3.1 Cell-Based Myocardial Tissue Repair/Regeneration Technologies
3.1.1 Graft Types
3.1.2 Cellular Therapy Administration
3.1.3 Clinical Experience
3.1.4 Procedure Volumes Forecast
3.2 Gene-Based Myocardial Tissue Repair/Regeneration Technologies
3.2.1 Therapeutic Objectives
3.2.2 Therapeutic Approaches
3.3 Cardiac Structural Support and Modification Technologies
3.3.1 Direct Cardiac Compression
3.3.2 Myocardial Support and Remodeling
3.3.3 Surgical Ventricular Restoration
3.3.4 Procedure Volumes Forecast
Exhibit 3-1: Selected Types of Cells under Investigation for Myocardial Tissue Repair/Regeneration
Exhibit 3-2: Cell-Based Myocardial Tissue Repair/Regeneration, Procedure Volumes Forecast, 2007-2011
Exhibit 3-3: Cardiac Support/Modification, Procedure Volumes Forecast, 2007-2011
4. CURRENT AND EMERGING MARKETS FOR SELECTED MYOCARDIAL REVASCULARIZATION PRODUCTS
4.1 Facilitated Anastomosis Devices
4.1.2 Market Forecast
4.2 Drug-Eluting Balloon Angioplasty Systems
4.2.2 Market Forecast
4.3 Drug-Eluting Stent Systems
4.3.2 Market Forecast
4.4 Transmyocardial Revascularization Systems
4.4.2 Market Forecast
4.5 Atherosclerosis Management Biotherapy Products
184.108.40.206 High-Density Lipoprotein-Boosting Biotherapies
220.127.116.11 Inflammatory Process-Targeting Biotherapies
4.5.2 Market Forecast
4.6 Combined Myocardial Revascularization Products Market Forecast
Exhibit 4-1: 2008, Selected Anastomosis Devices for Cardiac Applications
Exhibit 4-2: Facilitated Anastomosis Devices Used in Coronary Artery Bypass Graft Surgery, Market Forecast, 2007-2011
Exhibit 4-3: 2007, Market for Facilitated Anastomosis Devices Used in Coronary Artery Bypass Graft Surgery, Share by Supplier
Exhibit 4-4: Drug-Eluting Balloon Angioplasty Systems for Treatment of In-Stent Restenosis, Market Forecast, 2007-2011
Exhibit 4-5: 2008, Selected Drug-Eluting Coronary Stents
Exhibit 4-6: Coronary Stent Systems, Market Forecast, 2007-2011
Exhibit 4-7: 2007, Drug-Eluting Coronary Stent Systems, Share by Supplier
Exhibit 4-8: 2008, Selected Transmyocardial Revascularization Products
Exhibit 4-9: Transmyocardial Revascularization Products, Market Forecast, 2007-2011
Exhibit 4-10: 2007, Transmyocardial Revascularization Products, Share by Supplier
Exhibit 4-11: 2008, Selected Atherosclerosis Management Biotherapies
Exhibit 4-12: Atherosclerosis Management Biotherapy Products, Market Forecast, 2007-2011
Exhibit 4-13: Current and Emerging Myocardial Revascularization Products, Combined Market Forecast, 2007-2011
5. CURRENT AND EMERGING MARKETS FOR SELECTED MYOCARDIAL REPAIR/REGENERATION PRODUCTS
5.1 Cell-Based Therapies for Myocardial Tissue Repair/Regeneration
5.1.1 Cell Types
18.104.22.168 Adipose-Derived Stem Cells
22.214.171.124 Skeletal Myoblasts
126.96.36.199 Human Adult Mesenchymal Stem Cells
188.8.131.52 Human Embryonic Stem Cells
184.108.40.206 Parthenogenetic Stem Cells
5.1.2 Market Forecast
5.2 Gene-Based Therapies for Myocardial Tissue Repair/Regeneration
5.2.1 Gene-Based Approaches under Investigation for the Enhancement of Myocardial Tissue Contractile Function and Prevention of Degenerative Ventricular Remodeling
220.127.116.11 AC6 Coding Gene
18.104.22.168 BARKct Coding Gene
22.214.171.124 SERCA2a and Phospholamban Coding Genes
126.96.36.199 S100A1 Coding Gene
5.2.2 Gene-Based Approaches under Investigation for the Regeneration of Myocardial Tissue
188.8.131.52 Myocardin Transcription Factor
184.108.40.206 p38 MAP Kinase
5.2.3 Market Analysis
5.3 Cardiac Structural Support/Modification Products
5.3.1 Direct Cardiac Compression Devices
5.3.2 Myocardial Support and Remodeling Devices
5.3.3 Surgical Ventricular Restoration Devices
5.3.4 Market Forecast
5.4 Combined Myocardial Repair/Regeneration Products Market Forecast
Exhibit 5-1: 2008, Selected Cell-Based Myocardial Tissue Repair/Regeneration Technologies in Development
Exhibit 5-2: Cell-Based Myocardial Tissue Repair/Regeneration Products, Market Forecast, 2007-2011
Exhibit 5-3: 2008, Selected Gene-Based Myocardial Tissue Repair/Regeneration Approaches under Investigation
Exhibit 5-4: 2008, Selected Surgical Ventricular Restoration Devices 5-46
Exhibit 5-5: Cardiac Support/Modification Devices, Market Forecast, 2007-2011
Exhibit 5-6: 2007, Cardiac Support/Modification Devices Market, Share by Supplier
Exhibit 5-7: Current and Emerging Myocardial Repair/Regeneration Products, Combined Market Forecast, 2007-2011
6. COMPANY PROFILES
6.1 Abbott Laboratories
6.2 Advanced Cell Technology, Inc.
6.3 Bioheart, Inc.
6.4 BIOTRONIK GmbH & Company KG
6.5 Boston Scientific Corporation
6.6 B. Braun Melsungen AG
6.7 Cardica, Inc.
6.8 Cardiogenesis Corporation
6.9 Chase Medical, Inc.
6.10 Cordis Corporation/Johnson & Johnson
6.11 Cytori Therapeutics, Inc.
6.12 Esperion Therapeutics, Inc.
6.13 Geron Corporation
6.14 GlaxoSmithKline PLC
6.15 Medtronic, Inc.
6.16 Merck & Company, Inc.
6.18 Osiris Therapeutics, Inc.
6.19 PLC Medical Systems, Inc.
6.20 Roche Group
APPENDIX: COMPANY LISTING
Acorn Cardiovascular, Inc.
Advanced Cell Technology, Inc.
Angioblast Systems, Inc.
AVANT Immunotherapeutics, Inc.
AVI BioPharma, Inc.
Bavaria Medizin Technologie GmbH
Biosensors International Group LTD
Biosense Webster, Inc.
BIOTRONIK GmbH & Company KG
Boston Scientific Corporation
B. Braun Melsungen AG
Bristol-Myers Squibb Company
CardioVascular BioTherapeutics, Inc.
Cardium Therapeutics, Inc.
Chase Medical, Inc.
Celldex Therapeutics, Inc.
Cellular Dynamics International, Inc.
Cytori Therapeutics, Inc.
DISA Vascular LTD
Esperion Therapeutics, Inc.
Geron Bio-Med LTD
Human Genome Sciences, Inc.
InSitu Technologies, Inc.
International Stem Cell Corporation
Intuitive Surgical, Inc.
Johnson & Johnson
Merck & Company, Inc.
MIV Therapeutics, Inc.
Novadaq Technologies, Inc.
Novare Surgical Systems, Inc.
Novartis Pharmaceutical Corporation
OncoMed Pharmaceuticals, Inc.
Osiris Therapeutics, Inc.
Paracor Medical, Inc.
PLC Medical Systems, Inc.
Relisys Medical Devices LTD
REVA Medical, Inc.
Sahajanand Medical Technologies LTD
Targeted Genetics Corporation
Tissue Genesis, Inc.
Vascular Concepts Group
Need help finding medtech research? Let us help you!